Referencias correspondientes a la pieza Met 237

1. Yusuf S, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med. 2016 May 26;374(21):2021-31.

2. Maningat P, et al. How do we improve patient compliance
and adherence to long-term statin therapy?. Curr Atheroscler Rep. 2013 Jan;15(1):291.

3. De Vera MA, et al.
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J ClinPharmacol. 2014 Oct;78(4):684-98.

4. Ferrannini E. et al. Fifty-two week efcacy and safety of vidagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009 Feb;11(2):157-66.

5. Stratton IM et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12.

6. Bosi E et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 11, 2009, 506-515

7. Jones Peter H y col. Efcacy and safety of ABT – 335 (fenobric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 201 (2009) 208-215

8. Keech AC et al. FIELD study investigator. Effects of long-term fenobrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus (FIELD Study): randomised controlled trial. Lancet 2005;366:1849-61

9. Keech AC et al. FIELD study investigator. Effect of fenobrate on the need for laser treatment for diabetic retinophaty (FIELD Study): a randomized control trial. Lancet 2007;370:1687-97

10. ACCORD Study Group. Effects of medical therapies on retinophaty progression in type 2 diabetes. N Engl. J Med 2010;363:233-44

11. Burgess D, et al. Effects of fenobrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenobrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation 2007;116:II_838 (abstract)

12. Effect of sevelamer and calcium on coronary artery calcication in patients new to haemodialysis. Geoffrey A. Block, David M. Spiegel,
James Ehrlich, Ravindra Mehta, Jill Lindberg, Ibert Dreisbach and Paolo Raggi. Kidney int, 2005; vol 68;1815-1824.

13. Long-term effects of
sevelamer hydrochloride on the calcium x phosphate product and lipid prole of haemodialysis patients. Glenn M Chertow, Steven K Burke,
Moureen A. Dillon, Eduardo Statopolsky. Nephrol Dial Transplante, 1999;14 2907-2914.

14. DiNicolantonio J., et al. “Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol)”. American Journal of Cardiology, Volume 111, Issue 5, Pages 765-
769, 1 March 2013.

15. Vitale C y col. Cardiovascular Diabetol 2005; 4-6